Expired patents mean big losses for Big Pharma
Jeremy Hobson: We’re getting a look at the health of the pharmaceutical industry today with earnings from companies like Johnson & Johnson, and Forest Laboratories. Analysts are seeing a bit of a downer from the drug companies this quarter.
Marketplace’s Jennifer Collins reports.
Jennifer Collins: Patents are about to expire on several blockbusters: Plavix, Zyprexa and cholesterol drug Lipitor. That last one is the bestselling drug in the world.
Lipitor advertisement: I trust my heart to Lipitor.
But millions of people may start trusting their hearts to generics once Pfizer loses that patent.
Chris Bowe: Thus they meet what they call a patent cliff.
Analyst Chris Bowe says Pfizer’s sales of Lipitor could drop by half in as little as a year. So Pfizer and other pharmaceutical companies need to have a stream of drugs in development. Miller Tabak’s Les Funtleyer says, these days, there’s been a shortage.
Les Funtleyder: Drugs are going generic faster than pharmaceutical companies can create new ones.
So what they can’t create, they buy.
Funtleyder: Which is why you’ve seen a lot of acquisitions.
And Funtleyder says that is likely to continue.
I’m Jennifer Collins for Marketplace.
There’s a lot happening in the world. Through it all, Marketplace is here for you.
You rely on Marketplace to break down the world’s events and tell you how it affects you in a fact-based, approachable way. We rely on your financial support to keep making that possible.
Your donation today powers the independent journalism that you rely on. For just $5/month, you can help sustain Marketplace so we can keep reporting on the things that matter to you.
